| Bcma polypeptides and uses thereof -> Monitor Keywords |
|
|
 
Bcma polypeptides and uses thereofRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai, Cyclopeptides, 25 Or More Peptide Repeating Units In Known Peptide Chain StructureBcma polypeptides and uses thereof description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20070249530, Bcma polypeptides and uses thereof. Brief Patent Description - Full Patent Description - Patent Application Claims
RELATED APPLICATION [0001] This application claims benefit from U.S. Provisional Application No. 60/540,271, filed Jan. 29, 2004, which is incorporated by reference herein in it entirety. FIELD OF THE INVENTION [0002] The present invention relates to new polypeptides that bind APRIL but little or no BAFF, bind BAFF but little or no APRIL, or bind APRIL and BAFF, nucleic acid molecules encoding the polypeptides and compositions comprising them. The present invention also relates to methods for preventing and treating immune related diseases and cancer using the compositions of this invention. The present invention also relates to methods for selecting inhibitors of APRIL and/or BAFF signaling using the polypeptides of this invention. BACKGROUND AND INTRODUCTION OF THE INVENTION [0003] The tumor necrosis factor receptors (TNFR) are a superfamily of transmembrane receptors involved in cell communication within the immune system. TNFR family members are structurally characterized by extracellular cysteine-rich domains (CRD) that form ligand-binding motifs. Generally, members of the TNFR superfamily found on B or T cells are type I transmembrane proteins that have several CRDs (Bodmer, J. L., et al., (2002) Trends Biochem Sci 27:19-26). There is, however, a sub-group of TNFR proteins expressed by B cells that are type III transmembrane proteins and contain a reduced number of CRDs: B-Cell Maturation Antigen (BCMA), Transmembrane Activator and CAML Interactor (TACI), and BLyS (BAFF) Receptor 3 (BR3) (Gross, J. A., et al., (2000) Nature 404: 995-999; Marsters, S. A., et al., (2000) Curr Biol 10:785-788; Thompson, J. S., et al., (2001) Science 293:2108-2111; Yu, G., et al., (2000) Nat Immunol 1:252-256. The extracellular domain (ECD) of TACI contains two CRDs, the BCMA ECD comprises one CRD, and the ECD of BR3 contains only a partial CRD. Together with the receptor (Fn14) for the TWEAK ligand, BCMA and BR3 are the smallest members of the TNFR superfamily. TACI, BCMA and BR3 lack an intracellular death domain. It is believed that these receptors are involved in the survival, proliferation, and/or differentiation of a variety of cells. [0004] The TNF family member BAFF is the only known ligand for BR3. BAFF-dependent B cell proliferation appears to require BR3; however, BAFF has also been reported to bind TACI and BCMA (Shu, H. B., and Johnson, H. (2000) Proc Natl Acad Sci USA 97:9156-9161; Thompson, J. S., et al., (2001) Science 293:2108-2111; Yu, G., et al., (2000) Nat Immunol 1:252-256). APRIL (also known as TRDL-1, TALL-2 and TNFSF13A), the TNF family member most closely related to BAFF, binds TACI and BCMA (Marsters, S. A., et al., (2000) Curr Biol 10:785-788; Thompson, J. S., et al., (2001) Science 293:2108-2111; Yu, G., et al., (2000) Nat Immunol 1:252-256). Despite cross-reactivity with receptors, the expression patterns of BAFF and APRIL are distinct; BAFF is expressed by macrophages, monocytes, and dendritic cells, while APRIL is expressed by lymphoid cells and at elevated levels by some tumor cells (Hahne, M., et al., (1998) J Exp Med 188:1185-1190). [0005] Tight regulation of BAFF levels appears to be critical for B cell homeostasis. BAFF knockout mice display significant reduction in the development and survival of follicular and marginal B cells while mice expressing a BAFF transgene develop a lupus-like autoimmune syndrome (Gross, J. A., et al., (2000) Nature 404:995-999; Mackay, F., et al., (2001) Science 293:2111-2114; Khare, S. D., et al., (2000) Proc Natl Acad Sci USA 97:3370-3375). A BAFF-specific antagonist, BR3-Fc (Kayagaki, N., et al., (2002) Immunity 17, 515-524), together with studies on BAFF knockout mice (Schiemann, B., et al., (2001) Science 293:2111-2114), has been used to demonstrate the essential role of BAFF in B cell development. [0006] The role of APRIL in B cell homeostasis is less clear especially since APRIL knockout mice display normal B cell levels (E. Varfolomeev et al., (2004) Mol. Cell. Biol 24(3): 997-1006). However, several groups have reported on its activity in cell proliferation and T cell function. For example, APRIL has been shown to be capable of inducing the proliferation of certain tumors cell lines in vitro and in vivo (Hahne, M., et al., (1998) J. Exp. Med. 188:1185-1190). APRIL transgenic mice displayed augmented T cell independent B cell responses and increased survival of T cells (Stein J. et al. (2002) J Clin Invest 109:1587-98). APRIL expression has also been shown to be upregulated in many tumors including colon and prostate cancers (Hahne, M., et al., (1998) J Exp Med 188:1185-1190; Rennert, P., et al., (2000) J Exp Med 192:1677-1684; Kelly, K., et al., (2000) Cancer Res 60:1021-1027. [0007] Both BCMA-Fc and TACI-Fc can inhibit the proliferation of primary B cells stimulated by APRIL (Yu, G., et al. (2000) Nat. Immunol. 1:252-256). Studies have shown the attenuation of autoimmune lupus-like disease progression in mice with BR3-Fc treatment (e.g., Kayagaki, N., et al., (2002) Immunity 17:515-524). A soluble form of BCMA (BCMA-Fc) has been shown to inhibit tumor cell growth in Nu/Nu mice implanted with HT29 and A549 tumor cells (Rennert, P., et al. (2000) J. Exp. Med. 192:1677-1683). [0008] Several reports have described the nanomolar binding affinity of BAFF to BCMA (Marsters, S. A., et al., (2000) Curr Biol 10:785-788; Shu, H. B., and Johnson, H. (2000) Proc Natl Acad Sci USA 97:9156-9161; Yu, G., et al., (2000) Nat Immunol 1:252-256), however these studies used a bivalent BCMA receptor-Fc fusion construct that could result in measured affinities that are enhanced by avidity. Pelletier et al. has anecdotally reported that a monovalent BCMA-Fc fusion protein created by mutating its Fc region interacts with BAFF with low affinity (Pelletier, M et al. (2003) JBC 278(35):33127-33133). None of these reports explored or identified the residues in BCMA that determine specificity for its binding to APRIL or BAFF as a BCMA monomer or multimer. SUMMARY OF THE INVENTION [0009] The present invention provides new polypeptide molecules that bind APRIL but bind little or no BAFF, bind BAFF but little or no APRIL, bind APRIL and BAFF, or bind BAFF and/or APRIL with decreased affinity as compared to a native BCMA polypeptide. The polypeptides of this invention are useful for research or medicinal purposes, including treating and diagnosing diseases, detecting APRIL and BAFF levels and developing inhibitors of the APRIL and BAFF signaling pathways. The polypeptides of this invention include monomers and multimers. The present invention provides compositions comprising the polypeptides or the nucleic acid molecules of this invention, methods for producing and using the polypeptides, and nucleic acid molecules encoding the polypeptides of this invention. In one embodiment, the polypeptides of this invention are derived from a BCMA sequence, such as the sequence of the extracellular domain of human BCMA. [0010] In one embodiment, a monomeric polypeptide of this invention binds APRIL with an IC50 value equal to or less than 100 nM and binds BAFF with an IC.sub.50 value equal to or greater than 100 uM. In one embodiment, a multimeric polypeptide of this invention binds BAFF with an IC50 value equal to or less than 100 nM and binds APRIL with an affinity that is thirty fold weaker than native BCMA binding to APRIL. In another embodiment, a monomeric polypeptide of this invention binds to BAFF and APRIL with affinities within the same order of magnitude. In another embodiment, a multimeric polypeptide of this invention binds to APRIL with an affinity less than 100 nM or less than 10 nM, with little or no binding to BAFF. [0011] In one embodiment, a polypeptide of this invention is a BCMA variant that has been derived from a mammalian BCMA polypeptide sequence wherein at least one amino acid residue corresponding to a residue selected from the group consisting of Q10, E12, Y13, F14, I22, Q25 and R27 of FIG. 5 has been altered. According to one embodiment, the BCMA variant has at least one substitution corresponding to a mammalian BCMA residue selected from the group consisting of I22K, R27Y, R27A, Q25D, Y13S, Y13F and Y13A. In one preferred embodiment, the BCMA variant is derived from at least the cysteine-rich domain (CRD) of a mammalian BCMA polypeptide. In another preferred embodiment, the BCMA variant is derived from at least the extracellular domain (ECD) sequence of a mammalian BCMA. In yet a further embodiment, the CRD sequence from which the BCMA variant is derived is a CRD sequence of a human BCMA polypeptide (e.g., residues 8-41 of FIG. 5) (SEQ ID NO:22). According to another embodiment, the BCMA variant comprises at least one substitution corresponding to a mammalian BCMA residue at I22K. [0012] In one embodiment, the BCMA variant comprises alterations at an amino acid residue corresponding to I22 and an amino acid residue corresponding to any one of the group consisting of F14 and Q25 of FIG. 5. In one preferred embodiment, the BCMA variant is substituted with I22K in combination with any one or all of the group consisting of F14A and Q25A. In another embodiment, the BCMA variant comprises alterations at an amino acid residue corresponding to R27 and a residue corresponding to any one of the group consisting of Y13 and Q25 of FIG. 5. In one further embodiment, the BCMA variant is substituted with at least R27Y or R27A in combination with Y13S, Y13F or Y13A. In another embodiment, the BCMA variant is substituted with Q25D in combination with R27Y or R27A (Q25D/R27 variant). In another embodiment, the Q25D/R27 variant is further substituted with Y13S, Y13F or Y13A. [0013] In one embodiment, a polypeptide of this invention that binds APRIL comprises the sequence of Formula I: TABLE-US-00001 (SEQ ID NO:1) C-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Y-X.sub.7-D-X.sub.9-L X.sub.11-X.sub.12-X.sub.13-C-K-X.sub.16-C- X.sub.18-X.sub.19-X.sub.20-C-X.sub.22-X.sub.23-X.sub.24-X.sub.25-X.sub.26-- X.sub.27-X.sub.28-X.sub.29-C- X.sub.31-X.sub.32-X.sub.33-C (Formula I) [0014] wherein X.sub.11 is any amino acid residue except A; [0015] wherein X.sub.2, X.sub.3, X.sub.4, X.sub.5, X.sub.7, X.sub.9, X.sub.11, X.sub.12, X.sub.13, X.sub.16, X.sub.18, X.sub.19, X.sub.20, X.sub.22, X.sub.23, X.sub.24, X.sub.25, X.sub.26, X.sub.27, X.sub.28, X.sub.29, X.sub.31, X.sub.32, X.sub.33 are any amino acid except cysteine. [0016] In a further embodiment, the polypeptide comprising Formula I further comprises the sequence NSVKGT linked carboxy-terminal to the thirty-fourth residue of Formula I. [0017] In a further embodiment, X.sub.11 is L, I or V in Formula I (SEQ ID NO:3). In another embodiment, X.sub.18 is selected from the group consisting of Q, D and A in Formula I (SEQ ID NO:4). In another embodiment of Formula 1, if X.sub.20 is Y, then X.sub.18 is D (SEQ ID NO:5). In another embodiment of Formula I, X.sub.20 is R (SEQ ID NO:28). In further embodiment, the sequence of Formula I is selected from the group consisting of: TABLE-US-00002 CSQNEYFDSLLHACKPCQLRCSSNTPPLTCQRYC, (SEQ ID NO:6) CSQNEYFDSLLHACKPCDLRCSSNTPPLTCQRYC, (SEQ ID NO:7) CSQNEYFDSLLHACKPCDLYCSSNTPPLTCQRYC, (SEQ ID NO:8) and CSQNEYFDSLVHACKPCQLRCSSNTPPLTCQRYC. (SEQ ID NO:9) [0018] In a further embodiment, the polypeptide comprising Formula I further comprises the sequence NSVKGT linked carboxy-terminal to the thirty-fourth residue of Formula I (SEQ ID NO:2). [0019] In one embodiment, a polypeptide of this invention that binds BAFF comprises the sequence of Formula II: TABLE-US-00003 (SEQ ID NO:10) C-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-D-X.sub.9-L-X.sub.11-X.s- ub.12-X.sub.13-C-X.sub.15-X.sub.16- C-X.sub.18-X.sub.19-X.sub.20-C-X.sub.22-X.sub.23-X.sub.24-X.sub.25-X.sub.2- 6-X.sub.27-X.sub.28-X.sub.29-C- X.sub.31-X.sub.32-X.sub.33-C (Formula II) [0020] wherein X.sub.6 is selected from the group consisting of Y, A, D, S and F; Continue reading about Bcma polypeptides and uses thereof... Full patent description for Bcma polypeptides and uses thereof Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Bcma polypeptides and uses thereof patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Bcma polypeptides and uses thereof or other areas of interest. ### Previous Patent Application: Absorption enhancing agents Next Patent Application: Compositions comprising polypeptides Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Bcma polypeptides and uses thereof patent info. IP-related news and info Results in 0.42214 seconds Other interesting Feshpatents.com categories: Medical: Surgery , Surgery(2) , Surgery(3) , Drug , Drug(2) , Prosthesis , Dentistry 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
